Our study suggests that somatic mutations in DNMT3A are significantly associated with poor short‐term neurological functional outcomes after stroke, especially in the subgroup of patients with higher hsCRP or IL‐6 levels at baseline and mRS scores at discharge. Here, DNMT3A is linked to stroke disorder.